

Job Description Medical Director

The company

TargED Biopharmaceuticals (TargED) is a Netherlands-headquartered biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis. TargED stands for Targeted Enzyme Delivery and the company's unique biological drugs use small antibodies ("VhH") to deliver enzymes to sites of thrombosis, enabling 'targeted' thrombolysis.

TargED's lead compound is TGD001, which provides effective thrombolysis for various forms of thrombosis. It is currently preclinically validated in two thrombotic indications for thrombotic thrombocytopenic purpura (aTTP – an orphan indication) and Acute Ischemic Stroke (AIS). The objective is to accelerate thrombolysis in all forms of thrombosis, irrespective of the thrombus composition. In 2022, TargED raised €45M of funding from an internal syndicate of VC investors and a loan from the Dutch government. TargED has a worldwide, exclusive license on the IP, covering TGD001 and variant fusion proteins.

TargED has a strong founding leadership team consisting of:

- CEO & co-founder Kristof Vercruysse, with 20 years' worth of drug development experience, and 13 years in the TTP field;
- CSO & co-founder Steven De Maat, PhD, with 10 years of experience as a technical expert in protein engineering, and the inventor of TGD001;
- COO & co-founder Marc Van Moorsel, PhD, with 5 years' experience in translational business development in nanomedicines;
- CDO Gerben van 't Klooster, PhD, with 30 years of experience in drug development and senior roles in Galapagos and Tibotec;
- CMO Josi Holz, MD, with 25 years of experience in pharmaceutical drug development and managerial positions at Ablynx, Gilead Sciences, and LEO Pharma.

TargED's objectives over the coming years is to grow as a company and achieve the following milestones:

- Deliver a full CMC (non GMP and GMP) and toxicology program in 2024 enabling phase I study in Healthy Volunteers in 2025, including preliminary PoC in patients
- For Acquired Thrombotic Thrombocytopenic Purpura (aTTP), deliver the successful completion of a pivotal study in 2026
- Deliver the successful completion of a Phase II PoC study for AIS by the end of 2026

Search

TargED is a small, virtual company (approx. 10FTE over 15 persons), comprising a core of full-time employees and a number of highly experienced consultants and advisors. The plan is to stay

both virtual and lean, however, with funding secure and TGD001 rapidly progressing through preclinical development and towards the clinic, there is a requirement to strengthen the team with the appointment of a **Medical Director** for approximately 0.6 FTE at start up to 1.0 FTE. The starting date is to be discussed.

The role and responsibilities

The Medical Director will be accountable for the medical oversight of the clinical trials, for medical review and communication of data, and for providing medical input into regulatory documents. More specific, as Medical Director, you will be responsible for:

- Directing study design, protocol development and execution of clinical research in healthy volunteers (Phase 1) and patients (Phase 2), in the field of thrombosis
- Contributing to the overall medical strategy of the clinical development plan of TGD001, and leading the execution of the plan, as well as giving in-depth medical input on potential new projects and on the preclinical development of novel candidates
- Support the development of case report forms, perform medical monitoring, liaise with investigators and site personnel, perform preliminary and exploratory data analyses on clinical trials, author clinical study reports, provide input on publication materials, and participate in advisory boards
- Generating/reviewing clinical components of key documents supporting registration, market access, and future commercialization of TGD001, and annual safety updates, as appropriate
- Ensuring an appropriate quality of all clinical documents (e.g. Investigators' Brochure, protocols, study reports, clinical components of regulatory submissions, safety related documents).
- Acting as a medical expert in TargED's Development Team, and have the ability to lead interactions with external stakeholders (e.g. regulatory authorities, key opinion leaders, advisory boards, patient advocacy groups) and internal decision boards
- Attend relevant congresses or other relevant fora to maintain up-to-date scientific/medical knowledge

Moreover, you shall:

- Oversee the safety of TGD001 (and potential follow-on compounds), including the safety aspects of patients in clinical studies and signal detection
- Act as Study Lead and, when needed, represent the program or disease area
- Provide input to key external presentations
- Plan and execute publications/clinical communication strategy in coordination with Scientific Communications.
- Provide on-boarding, training and mentoring support to team members, and contribute to the hiring and performance evaluations
- Other related tasks may be assigned from time to time

What do we expect from you?

TargED expects its Medical Director to:

- Have a MD background with a minimum 3 years of industry experience, preferably within the fields of thrombosis and/or hematology
- Have experience as a responsible medical officer overseeing clinical trial(s)
- Have strong knowledge of early clinical development (phase I/II) and clinical trial requirements from First in Human to Phase III studies
- Have the ability to represent TargED in a variety of internal and external settings
- Possess strong interpersonal, analytical and presentation skills
- Demonstrate success in teamwork within a matrix organization and ability to inspire trust among colleagues
- Maintain close attention to detail and the ability to anticipate and mitigate problems
- Be innovative, flexible, resilient, and visionary with the ability to seize opportunities
- Have the ability to prioritize, respond to directives, and work in a fast-paced and dynamic environment
- Be result and goal-oriented, committed to make a difference, and genuinely care to transform the lives of patients suffering from thrombosis
- Have excellent knowledge of MS Office 365
- Speak English fluently
- Be preferably operational from the Netherlands, or as minimum requirement be a European or US citizen
- Preferably available in the Utrecht office for at least 1 day per week (on Tuesday and/or Wednesday)

What can you expect from us?

Working with TargED Biopharmaceuticals encompasses an attractive salary, as well as a competitive rewards package of fringe benefits (bonus, equity), but - above all - working in an informal yet professional and international start-up environment with a team of colleagues that are both enthusiastic and driven to reach their goals (work hard, play hard). You will be encouraged to work independently and to take initiative in an inspirational work environment full of development opportunities.

The office (Utrecht) is easily accessible by public transport and has a parking should you come to the office by your own vehicle.

For more information please contact:

Marc van Moorsel

Chief Operating Officer

E: info@targedbio.com